This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0801) (NSCLC)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2010 by Zhejiang Cancer Hospital.
Recruitment status was:  Active, not recruiting
Information provided by:
Zhejiang Cancer Hospital Identifier:
First received: March 31, 2009
Last updated: February 23, 2011
Last verified: March 2010
Patients with inoperable Non-Small-Cell Lung Cancer will receive thoracic radiation therapy 66 Gy over 33 fractions,and concurrent with 2 cycles of chemotherapy with pemetrexed (500 mg/m2,d1,repeated every 3 weeks)and carboplatin (AUC=5,d1,repeated every 3 weeks).

Condition Intervention Phase
Non-Small Cell Lung Cancer Drug: pemetrexed Drug: carboplatin Radiation: thoracic radiation Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Zhejiang Cancer Hospital:

Primary Outcome Measures:
  • tumor response rate [ Time Frame: Tumor assessments after completion of chemoradiotherapy and every 2 months ]

Secondary Outcome Measures:
  • overall survival [ Time Frame: baseline to date of death from any cause ]
  • time to progressive disease [ Time Frame: baseline to measured progressive disease ]
  • the safety profile [ Time Frame: every cycle ]
  • site of first failure in patients who develop progressive disease [ Time Frame: baseline to measured progressive disease ]

Estimated Enrollment: 63
Study Start Date: July 2008
Estimated Study Completion Date: July 2010
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
patients receiving pemetrexed, carboplatin and radiation therapy.
Drug: pemetrexed
500 mg/m2, IV, q 21 days x 2 cycles
Drug: carboplatin
AUC=5,IV,q 21 days x 2 cycles
Radiation: thoracic radiation
66 Gy over 33 fractions


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven non-small cell lung cancer (non-squamous cell carcinoma)
  • Presence of measurable disease by RECIST
  • Inoperable stage IIIA or IIIB
  • ECOG performance status 0-1
  • No prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy
  • Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital.

Exclusion Criteria:

  • Carcinoid tumor, small cell carcinoma of lung
  • Patients with any distant metastasis
  • History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix Any other morbidity or situation with contraindication for chemotherapy (e.g. active infection, myocardial infarction preceding 6 months, symptomatic heart disease including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive treatment)
  • Pregnant or lactating women, women who has not taken test of pregnancy (within 14 days before the first administration) and pregnant women
  • Women and men of childbearing potential who have no willing of employing adequate contraception
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00886678

China, Zhejiang
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Sponsors and Collaborators
Zhejiang Cancer Hospital
Principal Investigator: Ma Sheng lin, MD Zhejiang Cancer Hospital
  More Information

Responsible Party: Ma Shenglin, Xu Yaping, Zhejiang Cancer Hospital Identifier: NCT00886678     History of Changes
Other Study ID Numbers: ZhejiangCH01
Study First Received: March 31, 2009
Last Updated: February 23, 2011

Keywords provided by Zhejiang Cancer Hospital:
Non-Small Cell Lung Cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors processed this record on September 18, 2017